1. Home
  2. MNSB vs AGEN Comparison

MNSB vs AGEN Comparison

Compare MNSB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

N/A

Current Price

$23.47

Market Cap

162.9M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.05

Market Cap

208.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNSB
AGEN
Founded
2003
1994
Country
United States
United States
Employees
171
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.9M
208.2M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
MNSB
AGEN
Price
$23.47
$6.05
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
28.3K
8.4M
Earning Date
04-20-2026
05-12-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
$1.50
$107.63
Revenue Next Year
$3.77
N/A
P/E Ratio
$12.64
$5.86
Revenue Growth
N/A
89.95
52 Week Low
$17.86
$2.71
52 Week High
$25.29
$8.70

Technical Indicators

Market Signals
Indicator
MNSB
AGEN
Relative Strength Index (RSI) 45.10 70.51
Support Level $22.00 $3.09
Resistance Level $25.16 $8.70
Average True Range (ATR) 0.56 0.75
MACD -0.14 0.17
Stochastic Oscillator 35.41 52.68

Price Performance

Historical Comparison
MNSB
AGEN

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: